FDA warned Nexlife that its website labels for compounded semaglutide and tirzepatide falsely suggest Nexlife is the compounder.
What happened
During a March 2026 review of Nexlife’s website, FDA found offers of compounded semaglutide and tirzepatide products. The pictured labels showed “Nexlife” as if Nexlife made the drugs, but FDA says it is not the compounder. FDA cited this as false or misleading labeling and advertising.
What FDA found
The website labels for compounded semaglutide and tirzepatide show “Nexlife” in a way that suggests Nexlife made the drugs, but it did not.
FD&C Act § 502(a) [21 U.S.C. § 352(a)]The website’s promotion of these compounded drugs is false or misleading.
FD&C Act § 502(bb) [21 U.S.C. § 352(bb)]The drugs were sent or offered for shipment across state lines in violation of the law.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Nexlife to respond within 15 business days with steps taken, including identifying who produces the compounded drugs, providing sample labeling, and fixing or removing other false or misleading website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- online pharmacies and website marketers of compounded drugs
- contract manufacturers whose products are labeled with another firm’s name
This is a summary. Read the original letter on fda.gov.